The Democrats shepherding Pelosi’s drug pricing bill have taken plenty of campaign cash from pharma

A version of this story appeared in this week’s D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.

WASHINGTON — The fate of Nancy Pelosi’s sweeping drug pricing bill rests in the hands of lawmakers who received more campaign contributions from the pharmaceutical industry than almost all other Democrats, according to a STAT review of campaign finance records.